Preeti Ramadoss, PhD

The addition of apalutamide to androgen deprivation treatment improved time to pain progression and other quality-of-life out­come measures in patients with metastatic castration-sensitive prostate cancer in the phase III TITAN trial.

Frequencies of certain genomic mutations associated with upper tract urothelial carcinoma versus urothelial carcinoma of the bladder may serve as the rationale for differ­ing response rates, Sumati V. Gupta, MD, said during a presentation of the data at the 11th European Multidis­ciplinary Congress on Urological Cancers.